Sanofi completed the investment in Resalis Therapeutics.

Sanofi, a pharmaceutical and healthcare company, completed the investment in Resalis Therapeutics, a RNA-based therapies developer. Financial terms were not disclosed. "The therapeutic landscape for obesity is rapidly evolving, and Sanofi’s investment highlights the potential of our approach. As we prepare to initiate a Phase 1 clinical trial for RES-010, this investment not only validates the robust data we’ve generated so far but also positions us to quickly advance through Phase 2 trials, bringing us closer to offering a potentially transformative treatment for patients living with obesity. We believe this will be a catalyst for further interest in this growing market," Alessandro Toniolo, Resalis Therapeutics CEO.